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Medial temporal lobe atrophy is
underreported and may have important
clinical correlates in medical inpatients
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Abstract
Background: The diagnostic workup in dementia includes brain imaging with reading focussed on signs of
cerebrovascular and neurodegenerative disease. We hypothesised that these findings may be underreported in
hospital patients, where imaging is often performed to rule out obvious pathology such as haemorrhage. In this
study, we review cranial computed tomography (CT) in medical inpatients for white matter changes and atrophy.
Our aim was to determine the clinical relevance of such findings and to what extent they were underreported.
Methods: Records from 200 inpatients aged over 60 years, who had been subjected to MMSE (mini-mental state
examination) and CDT (clock-drawing test), were reviewed for cranial CT. Transverse and coronal slices were
reassessed using visual rating scales regarding white matter changes (WMC), global cortical atrophy (GCA) and
medial temporal lobe atrophy (MTA). Findings were compared with the original radiology reports and cognitive
test results.
Results: Cranial CT had been performed in 94 of 200(47 %) patients. Of these, 58(62 %) had abnormal WMC,
35(37 %) abnormal GCA and 34(36 %) abnormal MTA. All three findings had associations with cognitive test results.
Abnormal MTA was associated with lower results on the overall score on MMSE and on orientation, memory and
language items. All three measurements were underreported in the original radiology reports; none of the 34
patients with abnormal MTA had been reported originally.
Conclusions: Signs of neurodegenerative disease, especially MTA, were highly underreported in cranial CT scans
performed in medical inpatients. At the same time, MTA seemed to hold the most important clinical correlates. Our
results suggest that MTA should be reported more regularly in this setting.
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Background
The need for improved diagnosis rates in dementia is
often emphasised [1, 2]. Today, one third of people in
the United Kingdom will have dementia at the end of
life, of which half will have been diagnosed [3, 4]. To im-
prove diagnosis rates, policy-makers have turned their
attention towards emergency hospitals, where dementia
prevalence is higher than in community settings [5–9].
The diagnostic workup in dementia includes cognitive
tests and brain imaging, using a CT scan or an MRI
[10–13]. Brain imaging is used to exclude intracranial
masses, to support clinical diagnosis and to differentiate
between diseases causing the dementia syndrome [14].
For example, a diagnosis of Alzheimer’s disease (AD) is
supported by medial temporal lobe atrophy (MTA),
while white matter changes (WMC) or infarcts are pre-
requisites for vascular dementia (VaD) [15–17].
We hypothesised that brain imaging could be used to
increase case-finding in a general hospital. Many elderly
inpatients undergo cranial CT, often with a low clinical
yield [18]. However, standardised assessments of white
matter changes and atrophy are usually not done, even
in patients with cognitive impairment [19]. In a previous
publication, we found that 73 % of a group of 200
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medical inpatients had abnormal results on cognitive
tests, of whom only 8 % were previously diagnosed [20].
In the present study, we reviewed routine cranial CT in
this group, focussing on white matter changes and atro-
phy. We assumed that these findings would be underre-
ported, as CT would primarily have been done to rule
out infarcts and haemorrhage. To assess the clinical rele-
vance of the radiological findings, they were compared
with cognitive tests.
Methods
The study was carried out at the Department of Internal
Medicine at Skåne University Hospital, a 700-bed ter-
tiary care facility in Malmö, Sweden. The present study
is a secondary analysis based on a previously published
intervention study, comprised of 200 patients seeking
emergency medical care for a wide variety of presenting
complaints. The inclusion has previously been described
in detail [21]. Included patients were over 60 years old,
living at home and had capability to perform crude cog-
nitive tests. Patients with terminal disease, language bar-
rier, deafness, aphasia, blindness and severe disease
associated with inability to communicate were excluded.
All patients in the original study who had undergone a
routine clinical CT were eligible for the present study.
Measurements
All data, except for the review of CT scans, have been
prospectively collected in a standardised way. Cognitive
tests were carried out at the wards, in private, by three
experienced testers who had received special training.
Cognitive tests were carried out when the patients had
been stabilised, patients with fever (>38 °C), electrolyte
imbalance, anaemia or elevated C-reactive protein
(>50 mg/L) were not tested until the condition had
subsided.
The mini-mental state examination (MMSE) was used
[22]. The maximal score is 30 points; a cut-off of < 24
points is often used to signify cognitive impairment in
medical inpatients. MMSE consists of ten items: orienta-
tion, registration, attention, recall, naming of objects,
repetition, 3-step command, reading, writing and figure
copying. The typical result in AD is low scores on orien-
tation and recall, abilities that are dependent on the
temporal lobe. In VaD the scores differ depending on
the areas involved but typically attention and executive
functions are affected [23].
We also used the clock-drawing test (CDT). The patient
was instructed to “draw the face of a clock and set the
time at ten past eleven”. Points from 0 (worst) to 5 (best)
were given, according to Shulman, with a score < 4 points
considered abnormal [24]. The CDT tests executive ability
and planning, subcortical functions and functions of the
frontal lobe.
Comorbidity was determined using interviews with pa-
tients and proxies as well as review of medical records.
Any conditions from interviews or diagnoses noted in
the medical record during the present or three preceding
hospitalisations were recorded. Combined comorbidity
was obtained using the Charlson comorbidity index [25].
Ethics statement
The study was performed according to the declaration
of Helsinki and all patients have given their written in-
formed consent. The original study and the secondary
analysis have both been approved by the regional ethics
committee at Lund University.
Brain imaging
No brain imaging was planned originally and therefore
routine CT scans were reviewed retrospectively for the
present study, regardless of indication. In dementia re-
search, MRI has primarily been used in order to grade
white matter changes and atrophy. However, when simple
visual rating scales are used, Wattjes et al. have shown that
results from CT and MRI are comparable [26].
We searched the hospital’s digital picture archiving
and communication system (PACS) for CT scans per-
formed ± 1 year from the admission in the original study.
If several CT had been performed, the one closest in
time to cognitive testing was selected for review. All pa-
tients in whom CT was performed, except one, had been
imaged at the radiology department at Skåne university
hospital in Malmö, the remaining patient underwent CT
at the radiology department at the same hospital, now in
Lund. All CT examinations were performed according
to routine clinical protocols at 16–64 detector row
equipment with automatic dose modulation. In all cases,
raw data were reconstructed in the axial (4.5 mm slices
in Malmö, 5 mm slices in Lund) and coronal (3 mm
slices) plane. Raw data as well as reconstructions were
saved at the hospital’s PACS system. Patient information
including the referral form is simultaneously available by
the radiological information system. For each CT scan,
the date and referring department was retrieved. We
also recorded if any symptoms of cognitive impairment
(“dementia”, “confusion”, “delirium”, “memory impair-
ment”) were mentioned in the referral form.
Visual rating scales
The images were reviewed by an experienced neuroradi-
ologist (DvW), who was blinded to all data except the
referral form. Three visual rating scales were used, see
below.
White matter changes (WMC)
White matter changes are assumed to result from inad-
equate perfusion and are characterized histopathologically
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by enlarged perivascular spaces, demyelination and gliosis.
In this study, WMC were scored in the axial plane accord-
ing to a modification of the four-point scale developed by
Fazekas et al. [27]. This scale has shown good to excellent
inter-rater reliability and good correlation with volumetry
[28]. The whole brain was rated as:
0: None or single punctate lesion
1: Multiple punctate lesions
2: Beginning confluency of lesions (bridging)
3: Large confluent lesions
Scores were dichotomised into normal (0–1 points) or
abnormal (2–3 points) as a score of 1 point may well
represent normal ageing [29, 30]. Also, the detection of
punctate lesions is unreliable on CT except perhaps
for the insula and thus a cut off of ≥ 2 was decided
reasonable.
Global cortical atrophy (GCA)
Global cortical atrophy represents the mean volume loss
of the cerebral cortex as a whole. In this context, the
GCA rating scale is used to give an overall estimate of
atrophy without regional bias. The GCA rating was
based on axial projections based using a four-point scale
[31]. This scale has been shown to have a lower good
inter- and intra-rater reliability [32]. Global atrophy was
rated as:
0: No cortical atrophy
1: Mild atrophy (opening of sulci)
2: Moderate atrophy (volume loss of gyri)
3: Severe atrophy “knife blade atrophy”
The scores were dichotomised into normal (0–1 points)
or abnormal (2–3 points) as a score of 1 point could rep-
resent normal aging [33].
Medial temporal lobe atrophy (MTA)
Medial temporal lobe atrophy represents loss of volume in
the hippocampal area. MTA is sensitive for Alzheimer’s
disease but not specific; it can be found in other demen-
tias as well [34]. In prospective studies in non-demented
subjects, MTA has been shown to predict future dementia
in general and Alzheimer’s disease in particular [35, 36].
The Scheltens scale was used to rate MTA, this scale has
excellent intra-rater and inter-rater reliability and signifi-
cant correlations with volumetry [37–40].
0: No atrophy
1: Widening of choroid fissure
2: As 1 + widening of temporal horn of lateral ventricle
3: As 2 + lowered height of hippocampal formation
4: As 3 + further volume loss of hippocampus.
The scores were dichotomised into normal (0–1 if
age < 75, 0–2 if age ≥ 75) and abnormal (2–4 if age < 75,
3–4 if age ≥ 75) as a certain amount of MTA occurs in
normal aging [41, 42]. If there was a discrepancy be-
tween left and right side, the highest degree of atrophy
was used. An example of MTA is illustrated in Fig. 1.
Original radiology reports
The original radiology reports were examined thoroughly
regarding any description of white matter changes, among
these “small vessel disease”, “leukoaraiosis”, “degenerative
vascular change”, as well as general atrophy and medial
temporal lobe atrophy. For all three measurements, the
same scoring was used.
NA: Finding not mentioned in original report
0: Finding excluded in original report.
1: Finding described as “mild” or not quantified
2: Finding described as “moderate”
3: Finding described as “severe”
Statistical method
We compared the patients who had undergone CT scans
with the ones who had not regarding baseline character-
istics. Student’s t-tests, chi-square tests and Mann–
Whitney U-tests were applied where appropriate. A
subgroup analysis was done for the patients whose refer-
rals had mentioned cognitive impairment.
To obtain an estimate of intra-rater reliability, 30 CT
scans were re-rated by the same rater, blinded to the
previous rating, with 12 months between the ratings.
Fig. 1 Medial temporal lobe atrophy. Example of abnormal medial
temporal lobe atrophy in a CT scan in a study patient representing
a score of 3 on the left side and 4 on the right side. This was not
mentioned in the original report. This patient had an MMSE score of
22 points with 0 points on the memory item. This patient had no
previous mentioning of cognitive impairment in medical records
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Intra-rater reliability was expressed with weighted Kappa
values.
The association between cognitive tests and the dichoto-
mised radiological measurements was studied using
Mann–Whitney U-tests. On MMSE, the total score as
well as the different items were compared. In addition, the
three measurements were compared to cognitive impair-
ment regarding sensitivity, specificity and predictive
values. Cognitive impairment was defined as having at
least one abnormal cognitive test result (MMSE < 24 or
CDT < 4).
All calculations were done using SPSS version 20.0. A
two-sided p value of < 0.05 was considered significant.
Results
In total, 94 of 200 patients (47 %) had undergone CT ±
1 year of cognitive tests. Of these, 26 were scanned be-
fore, 44 during and 24 after the index hospitalisation.
The median interval between CT and cognitive testing
was 12 days (interquartile range 1–132 days). The refer-
ral for CT was issued by the ED or a hospital ward in 87
patients, by outpatient clinics at the hospital in 5 pa-
tients and by GPs in 2 patients. Cognitive impairment
was mentioned in 35/94 (37 %) of referrals, see Fig. 2.
The patients who had undergone a CT scan had a
higher prevalence of hypertension and stroke. This
group was also more cognitively impaired; baseline data
are displayed in Table 1.
All three measurements were highly prevalent and
underreported in the original reports, see Table 2 for
exact scores and Fig. 3 for dichotomised values. Intra-
rater weighted Kappa values were good to excellent, with
0.90 for WMC, 0.77 for GCA, 0.94 for MTA (left) and
0.97 for MTA (right).
When cognitive impairment was mentioned in the re-
ferral, WMC reporting increased in the original radi-
ology reports. Upon review, abnormal MTA was more
prevalent in this subgroup, see Table 3.
All patients
n = 200





not mentioned n = 59
Cognitive impairment
mentioned n = 35
Fig. 2 Outline of the study. The original study comprised of 200
patients. Of these, 94 had performed a CT scan. In 35 of these,
cognitive impairment was mentioned in the referral
Table 1 Baseline data





Age 83.8 (8.3) 83.0 (8.0) 0.46
Female sex 63 % 67 % 0.66
Intervention in original study 55 % 44 % 0.12
Living alone 62 % 72 % 0.14
Ischemic Heart Disease 38 % 29 % 0.23
Heart Failure 30 % 26 % 0.53
Hypertension 42 % 56 % 0.047
COPD 24 % 15 % 0.15
Stroke/TIA 10 % 31 % <0.001
Diabetes 22 % 25 % 0.74
Cancer, nonskin 26 % 31 % 0.43
Diagnosed with dementia or MCI 6 % 10 % 0.42
Charlson comorbidity index 2.2 (1.4) 2.3 (1.6) 0.70
MMSE 23.9 (3.7) 21.6 (4.4) <0.001
CDT 3.8 (1.1) 3.0 (1.2) <0.001
All data are presented as mean (SD) or percentages. Abbreviations: MCI = mild
cognitive impairment, COPD = chronic obstructive pulmonary disorder,
TIA = transient ischemic attack, MMSE =mini-mental state examination
Table 2 Visual rating scales (n = 94)
White matter changes (WMC) Original report Review
0 points 9 17
1 points 25 19
2 points 14 31
3 points 11 27
WMC not commented 35 (37 %) -
Global cortical atrophy (GCA)
0 points 8 15
1 points 22 44
2 points 4 30
3 points 0 5
GCA not commented 60 (64 %) -
Medial temporal lobe atrophy (MTA)
0 points 4 14
1 points 4 26
2 points 0 25
3 points 0 22
4 points NA 7
MTA not commented 86 (91 %) -
Table 2. Frequency of the radiological findings as described in the original
report and on review. The original reports were rated 0 (finding negated), 1
(mild), 2 (moderate), 3 (severe). For the review scores, the Fazekas, Pasquier
and Scheltens scales were used for WMC, GCA and MTA respectively.
NA: not applicable since the original reports were rated from 0 to 3
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Visual rating scales vs. cognitive tests
Abnormal WMC was associated with lower scores on the
MMSE item of repetition (p = 0.012). Abnormal GCA was
associated with lower scores on MMSE total (p = 0.009),
orientation (p = 0.04), 3 step command (p = 0.010), figure
copying (p = 0.03) and on clock-drawing test (p = 0.02).
Abnormal MTA was associated with lower scores on
MMSE total (p = 0.006), orientation (p = 0.03), recall
(p < 0.001) and reading (p = 0.018). When compared to
cognitive impairment in general, the sensitivity, specificity
and predictive values are shown in Table 4.
Other radiology findings
Thirty-two patients had other findings, apart from
WMC, GCA and MTA, upon review. Thirty of these
were found to have cerebral infarctions/haemorrhage in
the parenchyma. The white matter changes attributed to
infarct areas were not included in the rating of WMC.
One patient had a small residue of a previous subdural
haematoma and one patient had (<5 mm) bilateral
hygromas. When dichotomised into absent/present,
other findings were not associated with lower scores on
MMSE or CDT (p = 0.41 and p = 0.59, respectively)
Discussion
In this study, WMC, GCA and MTA were rated in cranial
CT:s of a general hospital population. All three measures
were found to be highly prevalent, underreported and had
seemingly important clinical correlates. This held espe-
cially for MTA, in spite of MTA being easy to assess on
routine CT scans that include coronal reconstruction.
The underreporting of MTA may have several reasons.
Firstly, emergency (<24 hours) cranial CT in the non-
trauma population is performed on a wide variety of indi-
cations in search of findings requiring immediate attention.
Thus, referrals often inquire for signs of acute ischemia,
haemorrhage, and other conditions. Hypothetically, the
radiologist is likely to reply to these specific questions with-
out paying attention to findings related to chronic dis-
ease, such as MTA. However, radiological reports even
for ED referrals frequently mention findings such as
hypertrophic sinonasal mucosa in patients where the
clinical significance of such finding likely is low [43].
Also, as in this study, WMC are quite often reported,
albeit having little or no clinical significance in the
acute situation. Thus, habits among radiologists seem
to influence reporting.
Secondly, MTA could be underreported since radiolo-
gists may not have been trained to look for it and grade
its severity. For example, the radiology reporting initia-
tive that the Radiological Society of North America
brought forward in 2012 does not mention atrophy in its
template report and the ventricular system can only be


















62% 27% 37% 36% 0% abnormal when
reviewed
Fig. 3 Reporting of findings. Chart showing the reporting frequency
of abnormal findings next to the reviewed findings. WMC = white
matter changes, GCA = global cortical atrophy, MTA =medial temporal
lobe atrophy
Table 3 Analysis of the subgroup in which cognitive
impairment was mentioned in the referral





Age 83.6 (8.3) 81.8 (7.3) 0.27
Female sex 61 % 77 % 0.12
In intervention originally 44 % 43 % 1.00
Living alone 66 % 83 % 0.10
Charlson index 2.2 (1.5) 2.5 (1.7) 0.45
MMSE 22.5 (4.2) 20.1 (4.4) 0.009
Clock-drawing test 3.1 (1.2) 2.7 (1.3) 0.10
WMC not commented in
original report
27 (46 %) 8 (23 %) 0.03
GCA not commented in
original report
40 (68 %) 20 (57 %) 0.38
MTA not commented in
original report
54 (91 %) 32 (91 %) 1.00
WMC abnormal on review 34 (58 %) 24 (69 %) 0.38
GCA abnormal on review 20 (34 %) 15 (43 %) 0.51
MTA abnormal on review 16 (27 %) 18 (51 %) 0.03
Data are presented as mean (SD) or number (percentages). Abbreviations:
CI = Cognitive Impairment, MMSE =mini-mental state examination.
Table 4 Relationship with cognitive impairment
Property WMC GCA MTA
sensitivity 68 % 40 % 39 %
specificity 79 % 71 % 79 %
positive predictive value 92 % 91 % 91 %
negative predictive value 28 % 18 % 18 %
Properties of abnormal results on the three visual rating scales when
compared to cognitive impairment, defined as having at least one abnormal
cognitive test result (MMSE < 24 points or CDT < 4 points)
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Thirdly, there may be a hesitation in reporting findings
related to cognitive impairment when the referral lacks
such information. However, MTA is unspecific and oc-
curs in normal ageing as well as in small vessel disease
without cognitive impairment. Thus, mentioning MTA
does not imply a diagnosis of neurodegenerative disease
and may be performed in all patients. In addition, our
results show that when the referral did in fact include
information on cognitive impairment, only reporting of
WMC increased, not of MTA. Again, this suggests that
habits influence reporting rather than concern of over-
stating findings associated with neurocognitive disorders.
However, our results cannot justify the apparent habit of
reporting WMC more than MTA
GCA was also underreported, however not graded;
GCA is an unspecific finding, not connected to any spe-
cific disease, and possibly less reproducible and more
prone to inter- and intra-rater variation. In addition, the
cut-off for normalcy is not as well documented as for
MTA; most cognitively impaired as well as unimpaired
elderly may be graded as 1 or 2, leaving grade 3 only as
definitely pathological. However, grade 3 is not often en-
countered. The clinical importance of GCA is probably
restricted to longitudinal studies, such as for the evalu-
ation of long-term effects of stroke and trauma; however
GCA is reported here for completeness.
Regarding clinical associations, all three abnormal
radiological findings had high positive predictive values
when compared to cognitive tests. If a CT had been
done, an abnormal finding would be associated with a
90 % risk of having an abnormal cognitive test. Sensitiv-
ity and specificity for the three tests were lower; how-
ever, no-one would recommend performing CT in all
medical inpatients in order to detect cognitive impair-
ment. Rather, our results suggest that abnormal findings
should be reported when a CT has been done, regardless
of indication.
Among the three measurements, WMC had the weak-
est associations with cognitive tests, with the MMSE
item of repetition alone. Previous studies have shown
that when atrophy and WMC co-exist, the importance
of WMC is reduced, this could be an explanation why
WMC had such a small impact [44] Abnormal GCA had
several associations with MMSE items and with the
CDT, representing a global impairment. Abnormal MTA
had the strongest association, with memory impairment;
this association was the only one that would sustain a
conservative Bonferroni correction. In addition, MTA
was associated with lower scores on MMSE total, orien-
tation and language items. Together, this profile indi-
cates a possible clinical presentation of AD, which
would be supported by the finding of MTA. This is
clinically important as there is symptomatic treatment
for AD.
This study has several methodological issues related to
its retrospective design:
Firstly, there is a possibility that the original interven-
tion study may have affected the results, as the interven-
tions acknowledged cognitive impairment [21]. If so, any
bias would probably be towards increased reporting of
cognitive impairment, as more attention was being paid
to these symptoms. Secondly, there was a risk for selec-
tion bias as brain imaging was not planned originally
and only patients who had undergone a CT could be
reviewed. Therefore the findings regarding prevalence of
WMC, GCA and MTA may be overestimated and
should be interpreted cautiously.
Regarding the reliability of the CT scans, it is a weakness
that only one person performed the visual ratings. How-
ever, the rater was a highly experienced neuroradiologist
and the CT scans were performed on state-of-the-art
equipment using coronal reconstructions. Regarding
MTA, which is the focus of this paper, it has been shown
to be the visual rating scale with the highest inter-rater re-
liability, with Kappa ranging from 0.82 – 0.91 in recent
studies including coronal reconstructions [38, 40] These
studies also show excellent intra-rater reliability for MTA,
consistent with our results.
The validity of CT scans could be affected by the time
gap between CT and cognitive tests. Cognitive impairment
could have been due to delirium and non-existent at the
time of CT. However, white matter changes and atrophy
represent long-term processes in the brain parenchyma.
With a median time between scan and cognitive tests of
12 days, the scans were considered reasonably accurate.
To the best of our knowledge, this is the first study to
apply standardised visual ratings scales regarding WMC,
GCA and MTA on routine CT in a general hospital popu-
lation. The findings regarding prevalence and reporting
frequency need to be replicated at another location to de-
termine external validity. Most likely, this has to be done
in a retrospective way to avoid bias from awareness. The
results regarding clinical usefulness are promising, espe-
cially considering the heterogeneity of this population
compared to memory clinic populations. These should be
replicated in a prospective study.
Throughout this study, a special emphasis has been
put on MTA. One reason for this was that MTA was
the most underreported finding. Another reason was
that MTA combines a high reliability with important
clinical correlates in a way that the other two scales do
not. As both clinicians and radiologists in this setting
are probably unfamiliar with all of these visual rating
scales, MTA should probably be emphasised first.
Reporting of MTA could increase the yield of cranial
CT in this population by improved case-finding in cog-
nitive impairment and dementia. In addition, it could
possibly contribute to differential diagnosis, with
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abnormal MTA being associated with an AD-like pro-
file on cognitive tests.
Conclusions
We propose that MTA should be reported more regu-
larly on cranial CT in the general hospital setting. Given
the need for improved case-finding in dementia, we sug-
gest that abnormal MTA should be used as a red flag to
signal to the clinician that this patient should be offered
a workup regarding cognitive impairment.
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